Remove tag two-labs
article thumbnail

Grand Rounds February 16, 2024: Clinical Implications of the MINT Trial: p=0.07 (Jeffrey Carson, MD, MACP)

Rethinking Clinical Trials

Finally, heart failure and other safety outcomes were comparable in the two transfusion groups. Discussion Themes -When did you consent the patients – before or after the cath lab? There was a solid mix of pre- and post- cath lab. Learn more Read more about the MINT trial. Could you discuss the journal review process?

Trials 130
article thumbnail

New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW

Drug Discovery World

The seminars will include high profile speakers from pharma and biotech covering topics such as The Lab of the Future is Now, Data Handling and Choosing the Right Informatics System, The Sustainable Lab and The Remote Lab: Is This the Future? Making improvements to digitisation is a two-stage problem.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds September 16, 2022: Using Nationwide Registries to Conduct Pragmatic Randomized Trials: The DANFLU Program (Tor Biering-Sørensen, MD, PhD, MPH)

Rethinking Clinical Trials

The COlchicine Hypertension Trial (COHERENT) is a pragmatic Phase II trial that looked at only hypertension by using registry data to identify patients that receive at least two hypertension drugs. It wasn’t the intention to bypass clinicians but the only ones involved are in the study lab and with the vaccine company. Learn more.

Trials 130
article thumbnail

Almirall and IRB Barcelona team up to tackle skin disease

pharmaphorum

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny.

article thumbnail

Grand Rounds December 16, 2022: The Use of EHR-Agnostic Clinical Decision Support to Prevent Thromboembolism in Hospitalized Medically Ill Patients (Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC; Jeffrey Solomon, BFA)

Rethinking Clinical Trials

Developers worked to find the “sweet spot” in a solution that balanced the two priorities. More analysis is needed to confirm that hypothesis Tags #pctGR, @Collaboratory1 The post Grand Rounds December 16, 2022: The Use of EHR-Agnostic Clinical Decision Support to Prevent Thromboembolism in Hospitalized Medically Ill Patients (Alex C.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. We have the emergence of this new pillar of medicine, which is out of the lab and beyond clinical trials now. How can we make sure patients can access these treatments despite the high costs?

article thumbnail

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

” The team found two cellular proteins, called GSPT1 and UPF1, that interact with Ebola virus polymerase and restrict Ebola virus early in infection. ” These insights were made possible thanks to an enzyme, called split-TurboID, which is a biotin ligase engineered by the lab of Stanford University Professor Alice Ting, Ph.D.

Protein 52